Guidelines for treatment of HIV infected adults in Europe
News
20 February 2020
Retreatment of hepatitis C — sofosbuvir/velpatasvir/ voxilaprevir (SOF/VEL/VOX) 2
All consecutive patients receiving SOF/VEL/VOX in 27 centers in northern Italy from May – October 2018 were enrolled in a real life study. Read more
20 February 2020
Retreatment of hepatitis C — sofosbuvir/velpatasvir/ voxilaprevir (SOF/VEL/VOX) 1
In the RESOLVE study, 77 patients with hepatitis C who had previously failed direct acting antiviral therapy (DAA) were treated with SOF/VEL/VOX for 12 weeks. Read more
EACS Guidelines
Magazine